Forskolin

Forskolin is the textbook direct adenylyl-cyclase activator — beautiful mechanism, every pharmacology class uses it. The mechanism is real: cAMP↑ → CREB → BDNF/LTP in hippocampal slices. The human cognitive evidence is basically absent. Body-comp marketing is loud and weak. For Dylan: skip — better cAMP/BDNF tools already on the V5 roster with actual human data.

Forskolin is a labdane diterpene from the root of Coleus forskohlii (Indian coleus, used in Ayurveda for heart conditions, bronchitis, and as topical for eye/skin). It is the rare small molecule that directly and reversibly activates adenylyl cyclase (AC) — the membrane enzyme that converts ATP → cyclic AMP (cAMP). It binds a hydrophobic pocket on the catalytic core of AC, allosterically stabilizing the active conformation. This bypasses the entire G-protein-coupled receptor cascade upstream.

Because adenylyl cyclase is downstream of basically every Gs-coupled receptor in the body, forskolin is systemically promiscuous:

1. Central — the cAMP → CREB → BDNF / LTP story: In hippocampal neurons, cAMP activates PKA and Epac. PKA phosphorylates CREB (cAMP response element-binding protein), which is the canonical transcription factor for synaptic plasticity. CREB activation → BDNF, Arc, c-Fos, and other plasticity-related gene expression → late-phase LTP (long-term potentiation), the cellular substrate of long-term memory. In hippocampal slice preparations, forskolin reliably induces a chemical form of LTP. In rodent fear-conditioning, contextual learning, and Morris water maze paradigms, intra-hippocampal forskolin enhances memory consolidation. All of this is preclinical.

2. Peripheral — lipolysis, vasodilation, bronchodilation:

• Adipocytes: cAMP → PKA → hormone-sensitive lipase phosphorylation → triglyceride hydrolysis → free fatty acid release. The body-comp marketing thesis. In isolated adipocytes this is dramatic; in intact humans the lipolytic effect is much smaller and offset by re-esterification.
• Vascular smooth muscle: cAMP → relaxation → vasodilation → blood pressure drop. Used IV in heart failure trials briefly in the 1980s.
• Cardiac: Positive inotrope (cAMP → PKA → L-type Ca²⁺ channel phosphorylation). Tachycardia at higher doses.
• Bronchial smooth muscle: Bronchodilation. Inhaled forskolin was studied for asthma in the 1980s; never made it through to a marketed product.
• Ciliary body (eye): Reduces aqueous humor production → lowers intraocular pressure. Topical forskolin eye drops were used clinically for glaucoma in the 1980s, displaced by beta-blockers and prostaglandin analogues.
• Thyroid follicular cells: cAMP is the second messenger downstream of TSH. Forskolin stimulates T4/T3 release in vitro. Not clinically used.

3. The luteolin / artichoke / "Marius Romanian protocol" stack: The cAMP signal is terminated by phosphodiesterases (PDEs), which hydrolyze cAMP → AMP. PDE4 is the dominant cAMP-degrading PDE in CNS and inflammatory cells. Luteolin (a flavone abundant in artichoke leaf extract) is a moderately selective PDE4 inhibitor. The logic of stacking forskolin (cAMP production↑) with luteolin (cAMP destruction↓) is mechanistically sound: you raise the equilibrium cAMP concentration from both sides. This protocol is widely attributed online to "Marius the Romanian" (an early-2010s Reddit/Longecity user who popularized it, sometimes called the "Marius protocol" or "Romanian protocol"). The conceptual framework is correct; the clinical evidence in humans for memory or learning is still essentially zero. The same logic underlies actual pharmaceutical PDE4 inhibitors (rolipram, roflumilast, BPN14770) — and those are blocked by emesis at therapeutic doses. Forskolin + luteolin is the "OTC version" of that idea.